Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: A nanomedicine approach to treat drug-resistant breast cancer

Nanomedicine

Volumn 8, Issue 12, 2013, Pages 1943-1954

  Bharali, Dhruba J ^a   Yalcin, Murat ^a,b   Davis, Paul J ^a,c   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ULUDAG UNIVERSITY   (Turkey)

^c ALBANY MEDICAL COLLEGE   (United States)

Author keywords

angiogenesis; breast cancer; chick chorioallantoic membrane; MCF7 breast cancer cell; nanoparticle; tetrac; thyroid hormone

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; INTEGRIN RECEPTOR; NANOPARTICLE; POLYGLACTIN; TETRAIODOTHYROACETIC ACID; THYROID HORMONE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CELL NUCLEUS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHORIOALLANTOIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FEMALE; MOUSE; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LACTIC ACID; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; POLYGLYCOLIC ACID; THYROXINE;

EID: 84887408474     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.200     Document Type: Article

References (46)

1. Bharali DJ, Mousa SA. Emerging nanomedicines for early cancer detection and improved treatment: Current perspective and future promise. Pharmacol. Ther. 128(2), 324-335 (2010
2. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56(11), 1649-1659 (2004 (Pubitemid 39177694)
3. Nagahara LA, Lee JS, Molnar LK et al. Strategic workshops on cancer nanotechnology. Cancer Res. 70(11), 4265-4268 (2010
4. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7(11), 653-664 (2010
5. Kim K, Kim JH, Park H et al. Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J. Control. Release 146(2), 219-227 (2010
6. Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: A concise review. Nanomedicine 1(3), 193-212 (2005 (Pubitemid 43963632)
7. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol. Res. 62(2), 90-99 (2010
8. Yu DH, Lu Q, Xie J, Fang C, Chen HZ. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials 31(8), 2278-2292 (2010
9. Serda RE, Godin B, Blanco E, Chiappini C, Ferrari M. Multi-stage delivery nanoparticle systems for therapeutic applications. Biochim. Biophys. Acta 1810(3), 317-329 (2010
10. Mahmoudi M, Sant S, Wang B, Laurent S, Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs): Development, surface modification and applications in chemotherapy. Adv. Drug Deliv. Rev. 63(1-2), 24-46 (2010
11. Smith AM, Duan H, Mohs AM, Nie S. Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv. Drug Deliv. Rev. 60(11), 1226-1240 (2008
12. Spiers ID, Eyles JE, Baillie LW, Williamson ED, Alpar HO. Biodegradable microparticles with different release profiles: Effect on the immune response after a single administration via intranasal and intramuscular routes. J. Pharm. Pharmacol. 52(10), 1195-1201 (2000
13. Lu JM, Wang X, Marin-Muller C et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev. Mol. Diagn. 9(4), 325-341 (2009
14. Roy A, Singh MS, Upadhyay PK, Bhaskar S. Combined chemo-immunotherapy as a prospective strategy to combat cancer: A nanoparticle based approach. Mol. Pharm. 7(5), 1778-1788 (2010
15. Wikingsson L, Sjoholm I. Polyacryl starch microparticles as adjuvant in oral immunization, inducing mucosal and systemic immune responses in mice. Vaccine 20(27-28), 3355-3363 (2002 (Pubitemid 35245819)
16. Duceppe N, Tabrizian M. Advances in using chitosan-based nanoparticles for in vitro and in vivo drug and gene delivery. Expert Opin. Drug Deliv. 7(10), 1191-1207 (2010
17. Park JH, Saravanakumar G, Kim K, Kwon IC. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv. Drug Deliv. Rev. 62(1), 28-41 (2010
18. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro-And nanoparticles in drug delivery. J. Control. Release 100(1), 5-28 (2004 (Pubitemid 39445982)
19. Yadav KS, Sawant KK. Formulation optimization of etoposide loaded PLGA nanoparticles by double factorial design and their evaluation. Curr. Drug Deliv. 7(1), 51-64 (2010
20. Shoyele SA. Controlling the release of proteins/peptides via the pulmonary route. Methods Mol. Biol. 437, 141-148 (2008
21. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54(5), 631-651 (2002 (Pubitemid 35247520)
22. Bergh JJ, Lin HY, Lansing L et al. Integrin aVb3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-Activated protein kinase and induction of angiogenesis. Endocrinology 146(7), 2864-2871 (2005 (Pubitemid 41002793)
23. Mousa SA, O'Connor L, Davis FB, Davis PJ. Proangiogenesis action of the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated. Endocrinology 147(4), 1602-1607 (2006
24. Lin HY, Tang HY, Shih A et al. Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-Apoptotic. Steroids 72(2), 180-187 (2007 (Pubitemid 46273502)
25. Davis FB, Mousa SA, O'Connor L et al. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ. Res. 94(11), 1500-1506 (2004 (Pubitemid 38780323)
26. Lin HY, Davis PJ, Tang HY et al. The pro apoptotic action of stilbene-induced COX 2 in cancer cells: Convergence with the anti-Apoptotic effect of thyroid hormone. Cell Cycle 8(12), 1877-1882 (2009
27. Mousa SA, Davis FB, Mohamed S, Davis PJ, Feng X. Pro-Angiogenesis action of thyroid hormone and analogs in a 3D in vitro microvascular endothelial sprouting model. Int. Angiol. 25(4), 407-413 (2006 (Pubitemid 46351000)
28. Davis FB, Tang HY, Shih A et al. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res. 66(14), 7270-7275 (2006 (Pubitemid 44197708)
29. Moreno M, de Lange P, Lombardi A, Silvestri E, Lanni A, Goglia F. Metabolic effects of thyroid hormone derivatives. Thyroid 18(2), 239-253 (2008 (Pubitemid 351271526)
30. Glinskii AB, Glinsky GV, Lin HY et al. Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 8(21), 3554-3562 (2009
31. Rebbaa A, Chu F, Davis FB, Davis PJ, Mousa SA. Novel function of the thyroid hormone analog tetraiodothyroacetic acid: A cancer chemosensitizing and anticancer agent. Angiogenesis 11(3), 269-276 (2008
32. Hercbergs A, Davis PJ, Davis FB, Ciesielski MJ, Leith JT. Radiosensitization of GL261 glioma cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 8(16), 2586-2591 (2009
33. Mousa SA, Bergh JJ, Dier E et al. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 11(2), 183-190 (2008
34. Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Preparation of poly(dl-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int. J. Pharm. 187(2), 143-152 (1999 (Pubitemid 29443894)
35. Song C, Labhasetwar V, Cui X, Underwood T, Levy RJ. Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: Results with an acute dog model. J. Control. Release 54(2), 201-211 (1998 (Pubitemid 28342699)
36. Yalcin M, Bharali DJ, Dyskin E et al. Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma. Thyroid 20(3), 281-286 (2010
37. Yalcin M, Dyskin E, Lansing L et al. Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid. J. Clin. Endocrinol. Metab. 95(4), 1972-1980 (2010
38. Yalcin M, Bharali DJ, Lansing L et al. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res. 29(10), 3825-3831 (2009
39. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr. Rev. 31(2), 139-170 (2010
40. Davis PJ, Davis FB, Mousa SA. Thyroid hormone-induced angiogenesis. Curr. Cardiol. Rev. 5(1), 12-16 (2009
41. Davis PJ, Davis FB, Mousa SA, Luidens MK, Lin HY. Membrane receptor for thyroid hormone: Physiologic and pharmacologic implications. Annu. Rev. Pharmacol. Toxicol. 51, 99-115 (2011
42. Hercbergs AH, Ashur-Fabian O, Garfield D. Thyroid hormones and cancer: Clinical studies of hypothyroidism in oncology. Curr. Opin. Endocrinol. Diabetes Obes. 17(5), 432-436 (2010
43. No authors listed. Nanotechnology in Health Care: US Industry Study with Forecasts to 2011, 2016 and 2021. The Freedonia Group, OH, USA (2007
44. No authors listed. The Nanotech Report™: Investment Overview and Market Research for Nanotechnology. Lux Research, Inc., MA, USA (2006
45. Bharali DJ, Lucey DW, Jayakumar H, Pudavar HE, Prasad PN. Folate-receptor-mediated delivery of InP quantum dots for bioimaging using confocal and two-photon microscopy. J. Am. Chem. Soc. 127(32), 11364-11371 (2005 (Pubitemid 41176898)
46. Klejbor I, Stachowiak EK, Bharali DJ et al. ORMOSIL nanoparticles as a nonviral gene delivery vector for modeling polyglutamine induced brain pathology. J. Neurosci. Methods 165(2), 230-243 (2007 (Pubitemid 47225124)